TRANSVAC: New Vaccines Faster
TRANSVAC is a collaborative infrastructure project funded by the European Commission (EC), initially under the 7th Framework Programme (FP7) and currently under Horizon 2020. The project is a joint effort of leading European groups working in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of EC vaccine projects by implementing a permanent research infrastructure for early vaccine development.
OPEN CALL
Submit your application for Vaccine Development Services and Training
Services at all stages
of the Vaccine R&D Pipeline
Free technical & theoretical courses at leading European centres
Support to development of vaccines against COVID19
Researchers developing vaccine candidates against #COVID19 are encouraged to apply and benefit
from all TRANSVAC2 services, such as:
Adjuvant formulation - Statens Serum Institut and Helmholtz Centre for Infection Research
Structural Biology - INSTRUCT
Systems Biology - Bioaster, UNISI, Leiden University
Animal models - CEA, BPRC and Helmholtz Centre for Infection Research
Clinical Trial Support - ECRIN
Check out all services available here
For specific inquiries on the details of each service available please contact directly service providers
SARS-CoV-2 illustration:Centers for Disease Control and Prevention (CDC) Image by: CDC/ Alissa Eckert, MS; Dan Higgins, MAMS
Latest News, events & more...
